查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519530

2024-2032 年癌症疫苗市场报告（按类型、技术、适应症、最终用户和地区）

Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球癌症疫苗市场规模达68亿美元。癌症发病率的增加、免疫疗法的进步、政府的倡议和资助、意识和教育的提高、技术的快速进步、战略合作和伙伴关係以及医疗保健支出的增加是推动市场的一些主要因素。

癌症疫苗是一种免疫疗法，旨在刺激人体免疫系统识别和攻击癌细胞。这些疫苗透过训练免疫系统识别特定的癌症相关抗原来发挥作用，这些抗原是在癌细胞上发现的可以触发免疫反应的物质。透过将这些抗原引入体内，癌症疫苗旨在激活免疫系统针对癌症的天然防御机制。癌症疫苗主要有两种类型，即预防性疫苗和治疗性疫苗。预防性癌症疫苗用于预防由传染源引起的某些类型的癌症，例如人类乳突病毒 (HPV) 或乙型肝炎病毒 (HBV)。这些疫苗刺激免疫系统产生对传染原的免疫反应，降低相关癌症的风险。另一方面，治疗性癌症疫苗旨在治疗现有的癌症。它们透过引入癌症特异性抗原或增强免疫系统对这些抗原的辨识来增强针对癌细胞的免疫反应。这些疫苗可以个人化，针对个别患者肿瘤细胞中存在的特定抗原。

全球癌症盛行率的上升是癌症疫苗市场的重要驱动力。由于癌症是导致死亡的主要原因，因此对有效的预防和治疗干预措施的需求不断增长。此外，包括癌症疫苗在内的免疫疗法已成为肿瘤学中一种有前景的治疗方法。新型免疫治疗策略的发展和现有免疫疗法的成功推动了对癌症疫苗的需求。除此之外，一般民众对癌症预防和早期发现重要性的认识也不断提高。教育活动、筛检计画和公众意识措施的增加导致对包括癌症疫苗在内的预防措施的需求更大。除此之外，市场也见证了製药公司、研究机构和学术机构之间的合作。这些伙伴关係促进了知识、资源和专业知识的交流，从而加速了癌症疫苗的开发和商业化。与此一致的是，不断增长的医疗保健支出，特别是在新兴经济体，提高了癌症疫苗的可近性和可负担性。可支配收入的增加、医疗基础设施的改善和保险覆盖范围的扩大正在促进市场的成长。此外，全球各国政府都在积极投资包括疫苗在内的癌症研究和开发，这正在创造积极的市场前景。

癌症疫苗市场趋势/驱动因素：

免疫疗法的进展

免疫疗法透过利用免疫系统的力量来瞄准和摧毁癌细胞，彻底改变了癌症治疗。免疫疗法（包括检查点抑制剂和过继性细胞疗法）的成功为癌症疫苗的开发和采用奠定了坚实的基础。癌症疫苗刺激针对肿瘤抗原的特异性免疫反应的能力进一步补充了现有的免疫治疗策略。这种协同作用刺激了对癌症疫苗作为联合疗法不可或缺的一部分的需求，从而导致其市场成长。

政府措施和资金

世界各国政府已经意识到迫切需要解决日益严重的癌症负担。因此，他们积极投资癌症研究、发展和医疗基础设施。政府为从事癌症疫苗研发的公司提供财政支持、补助和激励措施。此外，监管机构正在与疫苗开发商密切合作，以简化审批流程并促进市场准入。这些支持性政策和融资措施极大地促进了市场的成长，使企业能够投资于研究、临床试验和製造能力。

提高认识和教育

一般民众对癌症预防和早期检测的认识不断提高，对癌症疫苗的需求产生了深远的影响。公共卫生运动、教育计画和倡导团体的倡议都强调了疫苗接种作为预防某些癌症的措施的重要性。 HPV 和 HBV 疫苗等癌症相关感染预防性疫苗的成功进一步增强了癌症疫苗的重要性。随着人们对癌症预防和免疫的好处越来越了解，对癌症疫苗的需求预计将增加，从而推动市场成长。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球癌症疫苗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 预防癌症疫苗
    • 市场走向
    • 市场预测
  • 治疗性癌症疫苗
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依技术

  • 树突细胞癌症疫苗
    • 市场走向
    • 市场预测
  • 重组癌症疫苗
    • 市场走向
    • 市场预测
  • 抗原/佐剂癌症疫苗
    • 市场走向
    • 市场预测
  • 病毒载体和 DNA 癌症疫苗
    • 市场走向
    • 市场预测
  • 全细胞癌症疫苗
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依迹象

  • 子宫颈癌
    • 市场走向
    • 市场预测
  • 摄护腺癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 儿科
    • 市场走向
    • 市场预测
  • 成年人
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Anixa Biosciences Inc.
    • Dendreon Pharmaceuticals LLC
    • Dynavax Technologies Corporation
    • GSK plc
    • Merck & Co. Inc.
    • Moderna Inc.
    • OSE Immunotherapeutics
    • Providence Therapeutics
    • Sanofi SA
    • UbiVac Inc.
    • Vaccitech plc
Product Code: SR112024A5901

The global cancer vaccines market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 16.7 Billion by 2032, exhibiting a growth rate (CAGR) of 10.2% during 2024-2032. The increasing cancer incidence, advancements in immunotherapy, government initiatives and funding, growing awareness and education, rapid technological advancements, strategic collaborations and partnerships, and increasing healthcare expenditure are some of the major factors propelling the market.

Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. These vaccines work by training the immune system to recognize specific cancer-related antigens, substances found on cancer cells that can trigger an immune response. By introducing these antigens into the body, cancer vaccines aim to activate the immune system's natural defense mechanisms against cancer. There are two main types of cancer vaccines, namely preventive (prophylactic) and therapeutic vaccines. Preventive cancer vaccines are used to prevent certain types of cancer caused by infectious agents, such as human papillomavirus (HPV) or hepatitis B virus (HBV). These vaccines stimulate the immune system to produce an immune response against the infectious agent, reducing the risk of developing associated cancers. Therapeutic cancer vaccines, on the other hand, are designed to treat existing cancers. They work by boosting the immune response against cancer cells, either by introducing cancer-specific antigens or by enhancing the immune system's recognition of these antigens. These vaccines can be personalized, targeting specific antigens present in an individual patient's tumor cells.

The rising prevalence of cancer worldwide is a significant driver for the cancer vaccines market. With cancer being a leading cause of mortality, there is a growing demand for effective preventive and therapeutic interventions. Additionally, immunotherapy, including cancer vaccines, has emerged as a promising treatment approach in oncology. The development of novel immunotherapeutic strategies and the success of existing immunotherapies have propelled the demand for cancer vaccines. Other than this, there is a rising awareness among the general population about the importance of cancer prevention and early detection. Increased education campaigns, screening programs, and public awareness initiatives have resulted in a greater demand for preventive measures, including cancer vaccines. Besides this, the market has witnessed collaborations between pharmaceutical companies, research institutes, and academic institutions. These partnerships facilitate the exchange of knowledge, resources, and expertise, leading to accelerated development and commercialization of cancer vaccines. In line with this, the growing healthcare expenditure, particularly in emerging economies, has boosted the accessibility and affordability of cancer vaccines. Rising disposable incomes, improving healthcare infrastructure, and expanding insurance coverage are contributing to market growth. Moreover, governments across the globe are actively investing in cancer research and development, including vaccines, which is creating a positive market outlook.

Cancer Vaccines Market Trends/Drivers:

Advancements in immunotherapy

Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and destroy cancer cells. The success of immunotherapeutic approaches, including checkpoint inhibitors and adoptive cell therapies, has created a strong foundation for the development and adoption of cancer vaccines. The ability of cancer vaccines to stimulate a specific immune response against tumor antigens further complements existing immunotherapy strategies. This synergy has fueled the demand for cancer vaccines as an integral part of combination therapies, leading to their market growth.

Government initiatives and funding

Governments worldwide have recognized the urgent need to address the growing burden of cancer. As a result, they are actively investing in cancer research, development, and healthcare infrastructure. Governments provide financial support, grants, and incentives to companies engaged in cancer vaccine research and development. Additionally, regulatory agencies are working closely with vaccine developers to streamline approval processes and facilitate market access. These supportive policies and funding initiatives have significantly contributed to the growth of the market, enabling companies to invest in research, clinical trials, and manufacturing capabilities.

Growing awareness and education

Increased awareness among the general population about cancer prevention and early detection has had a profound impact on the demand for cancer vaccines. Public health campaigns, educational programs, and initiatives by advocacy groups have emphasized the importance of vaccinations as a preventive measure against certain cancers. The success of preventive vaccines for infections linked to cancer, such as HPV and HBV vaccines, has further reinforced the significance of cancer vaccines. As people become more knowledgeable about the benefits of cancer prevention and immunization, the demand for cancer vaccines is expected to increase, thus driving market growth.

Cancer Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cancer vaccines market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, technology, indication and end user.

Breakup by Type:

Preventive Cancer Vaccines

Therapeutic Cancer Vaccines

Preventive cancer vaccines dominate the market

The report has provided a detailed breakup and analysis of the market based on the type. This includes preventive cancer vaccines and therapeutic cancer vaccines. According to the report, preventive cancer vaccines represented the largest segment.

Preventive cancer vaccines have demonstrated significant success in reducing the incidence of specific cancers associated with infectious agents. Vaccines, such as the human papillomavirus (HPV) and hepatitis B virus (HBV), have proven effective in preventing cervical, anal, and certain types of liver cancer, respectively. The efficacy and safety of these vaccines have led to their widespread acceptance. Additionally, these vaccines offer a proactive approach to cancer prevention. They target specific infectious agents known to contribute to the development of certain cancers, thereby providing a direct means of prevention. This approach is especially appealing as it focuses on reducing the risk of developing cancer in the first place, rather than solely relying on early detection or treatment interventions. As public awareness of the benefits of preventive measures increases, individuals and healthcare providers are embracing the use of preventive cancer vaccines, thus contributing to the segment's market dominance. Other than this, preventive cancer vaccines align with global efforts to reduce the burden of cancer. Moreover, governments and healthcare organizations across the world have recognized the value of prevention in combating cancer and have implemented vaccination programs as part of their public health initiatives. These programs target specific populations, such as adolescents for HPV vaccination, to maximize the preventive impact. The extensive implementation of national immunization programs and the inclusion of preventive cancer vaccines in routine vaccination schedules further drive the market segment.

Breakup by Technology:

Dendritic Cells Cancer Vaccines

Recombinant Cancer Vaccines

Antigen/Adjuvant Cancer Vaccines

Viral Vector and DNA Cancer Vaccines

Whole-cell Cancer Vaccines

Recombinant cancer vaccines hold the largest share in the market

A detailed breakup and analysis of the market based on technology has also been provided in the report. This includes dendritic cells cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, viral vector and DNA cancer vaccines, and whole-cell cancer vaccines. According to the report, recombinant cancer vaccines accounted for the largest market share.

Recombinant technology allows for precise and controlled production of cancer vaccines. These vaccines are developed by inserting specific genes or DNA sequences encoding tumor antigens into a vector such as a virus or bacteria. This genetic engineering technique enables researchers to create vaccines that express tumor-specific antigens, effectively targeting cancer cells while minimizing potential side effects. The ability to tailor the vaccine's composition and antigen profile to match the specific characteristics of a patient's tumor makes recombinant cancer vaccines highly customizable and attractive in personalized medicine approaches. Additionally, recombinant vaccines have demonstrated favorable safety and efficacy profiles. The use of recombinant technology allows for the production of vaccines without using live or attenuated pathogens, reducing the risk of adverse events. Additionally, recombinant vaccines can induce a robust immune response by presenting tumor-specific antigens to the immune system in a controlled manner. This targeted immune response enhances the vaccine's efficacy in recognizing and attacking cancer cells. Other than this, this technology offers scalability and cost-effectiveness in vaccine production. The use of recombinant techniques allows for efficient large-scale production of vaccines, thus meeting the demand for widespread vaccination programs.

Breakup by Indication:

Cervical Cancer

Prostate Cancer

Others

The report has provided a detailed breakup and analysis of the market based on the indication. This includes cervical cancer, prostate cancer, and others.

Cervical cancer is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV). Vaccines targeting HPV have been successful in preventing cervical cancer. The market for cervical cancer vaccines is driven by the increasing awareness about the role of HPV in cervical cancer development, along with the implementation of national vaccination programs. Vaccines, such as Gardasil and Cervarix, have been developed specifically to prevent HPV infection and subsequent development of cervical cancer. These vaccines have shown remarkable efficacy in preventing HPV infections and reducing the incidence of cervical precancerous lesions. The market segment for cervical cancer vaccines is expected to grow as vaccination rates improve and more countries include HPV vaccination in their immunization programs.

Prostate cancer is the most common cancer among men, and the demand for effective treatment options is high. Vaccines targeting prostate cancer work by stimulating the immune system to recognize and attack prostate cancer cells. Sipuleucel-T (Provenge) is an example of an FDA-approved therapeutic vaccine for advanced prostate cancer. It is designed to boost the patient's immune response against prostate cancer cells. The market for prostate cancer vaccines is driven by the need for innovative treatment options that can improve overall survival and quality of life for patients. Additionally, the rising prevalence of prostate cancer, especially in aging population, contributes to the market growth. Moreover, ongoing research and clinical trials developing new prostate cancer vaccines, is further enhancing the potential of this market segment.

Breakup by End User:

Pediatrics

Adults

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes pediatrics and adults.

Pediatric patients, including infants, children, and adolescents, represent a crucial target population for cancer vaccines. Vaccination in pediatrics aims to prevent cancers associated with infectious agents, such as cervical cancer caused by HPV or liver cancer caused by HBV. Vaccinating children and adolescents against these infections can provide long-term protection and reduce the risk of developing associated cancers in adulthood. Government immunization programs and initiatives aimed at promoting pediatric vaccination have been instrumental in driving the market growth. Other than this, the demand for pediatric cancer vaccines is expected to increase with the increasing awareness about the benefits of early prevention and vaccination.

While pediatric vaccination focuses on preventing cancers in early stages of life, adult vaccination targets both preventive and therapeutic purposes. In terms of prevention, adult cancer vaccines primarily aim to protect against infectious agents that contribute to certain cancers, such as HPV-associated cancers, HBV-related liver cancer, and human immunodeficiency virus (HIV)-associated cancers. Additionally, therapeutic vaccines targeting specific antigens expressed by cancer cells are being developed for adult patients. These therapeutic vaccines are designed to stimulate the immune system and enhance the body's ability to recognize and attack cancer cells. The market for adult cancer vaccines is driven by the growing emphasis on preventive healthcare, increasing awareness regarding vaccination benefits in adults, and advancements in therapeutic vaccine research and development.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-developed healthcare infrastructure and advanced research capabilities. The region is home to numerous leading pharmaceutical and biotechnology companies, academic institutions, and research centers specializing in cancer research. This robust ecosystem fosters innovation, enabling the development and commercialization of cutting-edge cancer vaccines. The presence of well-established regulatory frameworks and stringent quality standards further supports the growth of the market in North America. Additionally, there is a high prevalence of cancer in this region, which is accelerating the adoption of effective treatment options, including cancer vaccines. The region experiences a significant burden of various cancers, such as lung, breast, prostate, and colorectal cancers. This increased incidence of cancer creates a substantial market opportunity for cancer vaccines as patients and healthcare providers seek novel therapies for prevention, treatment, and improved patient outcomes. Other than this, North America has a strong emphasis on preventive healthcare and vaccination programs. The region's healthcare systems prioritize disease prevention and public health initiatives, including immunization campaigns. Moreover, vaccination against infectious agents associated with certain cancers, such as HPV and HBV, is actively promoted, leading to a higher uptake of preventive cancer vaccines.

Competitive Landscape:

Key players are actively investing in research and development to advance the development of cancer vaccines. They are focused on identifying novel tumor antigens, optimizing vaccine formulations, and exploring innovative delivery systems. Healthcare companies are conducting extensive preclinical and clinical trials to demonstrate the safety, efficacy, and potential of their cancer vaccine candidates. These trials involve collaboration with healthcare institutions and involve a large patient population. By supervising rigorous clinical trials, they are gathering valuable data on the performance of their vaccines, demonstrating their efficacy, and paving the way for regulatory approvals and market entry. Other than this, key players are actively working on expanding market access for cancer vaccines. They are involved in obtaining regulatory approvals in various countries, ensuring manufacturing scalability, and establishing distribution networks. Companies are also focused on educating healthcare providers, patients, and the general public about the benefits of cancer vaccines. Marketing and promotional activities are carried out to create awareness, enhance adoption rates, and drive market growth. Besides this, they continue to invest in their product pipelines and drive innovation in the market by constantly exploring new vaccine candidates, improving existing formulations, and discovering novel approaches to enhance immune responses.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Anixa Biosciences Inc.

Dendreon Pharmaceuticals LLC

Dynavax Technologies Corporation

GSK plc

Merck & Co. Inc.

Moderna Inc.

OSE Immunotherapeutics

Providence Therapeutics

Sanofi S.A.

UbiVac Inc.

Vaccitech PLC

Recent Developments:

GSK Plc is actively involved in the development of cancer vaccines as part of its commitment to advancing healthcare. In 2022, the company invested £5.5 billion in R&D, 9% AER more than 2021, to enhance its pipeline of vaccines and medicines.

In October 2023, Merck announced that it will be jointly developing and commercializing mRNA-4157/V940 with Moderna. Moderna Inc. has been making recent developments in the cancer vaccines industry by working on mRNA vaccines for cancer treatment.

In 2023, OSE Immunotherapeutics is developing a cancer vaccine called Tedopi, which is the first cancer vaccine to demonstrate clinically meaningful efficacy results, along with a better safety and quality of life profile. It is currently in late-stage clinical development for lung cancer. The Phase 3 results of Tedopi have shown promising outcomes in the field of Immuno-Oncology. Additionally, a new patent has been granted to protect Tedopi as a therapeutic cancer vaccine.

Key Questions Answered in This Report

  • 1. How big is the global cancer vaccines market?
  • 2. What is the expected growth rate of the global cancer vaccines market during 2024-2032?
  • 3. What are the key factors driving the global cancer vaccines market?
  • 4. What has been the impact of COVID-19 on the global cancer vaccines market?
  • 5. What is the breakup of the global cancer vaccines market based on the type?
  • 6. What is the breakup of the global cancer vaccines market based on the technology?
  • 7. What are the key regions in the global cancer vaccines market?
  • 8. Who are the key players/companies in the global cancer vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Preventive Cancer Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Dendritic Cells Cancer Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Recombinant Cancer Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antigen/Adjuvant Cancer Vaccines
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Viral Vector and DNA Cancer Vaccines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Whole-cell Cancer Vaccines
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cervical Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Prostate Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Anixa Biosciences Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Dendreon Pharmaceuticals LLC
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Dynavax Technologies Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GSK plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Moderna Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 OSE Immunotherapeutics
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Providence Therapeutics
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UbiVac Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Vaccitech plc
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials

List of Figures

  • Figure 1: Global: Cancer Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Vaccines Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer Vaccines Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Cancer Vaccines Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Cancer Vaccines Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: Cancer Vaccines Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Cancer Vaccines Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cancer Vaccines (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cancer Vaccines (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cancer Vaccines (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cancer Vaccines (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cancer Vaccines (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cancer Vaccines (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cancer Vaccines (Pediatrics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cancer Vaccines (Pediatrics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cancer Vaccines (Adults) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cancer Vaccines (Adults) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: North America: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: North America: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: United States: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: United States: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Canada: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Canada: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Asia-Pacific: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Asia-Pacific: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: China: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: China: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Japan: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Japan: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: India: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: India: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: South Korea: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: South Korea: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Australia: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Australia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Indonesia: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Indonesia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Europe: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Europe: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Germany: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Germany: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: France: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: France: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: United Kingdom: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: United Kingdom: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Italy: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Italy: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Spain: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Spain: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Russia: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Russia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Latin America: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Latin America: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Brazil: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Brazil: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Mexico: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Mexico: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Middle East and Africa: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Middle East and Africa: Cancer Vaccines Market: Breakup by Country (in %), 2023
  • Figure 81: Middle East and Africa: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Global: Cancer Vaccines Industry: SWOT Analysis
  • Figure 83: Global: Cancer Vaccines Industry: Value Chain Analysis
  • Figure 84: Global: Cancer Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer Vaccines Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Cancer Vaccines Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: Cancer Vaccines Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Cancer Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cancer Vaccines Market: Competitive Structure
  • Table 8: Global: Cancer Vaccines Market: Key Players